Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis

Johnsson, H.J. and McInnes, I.B. (2015) Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis. Clinical and Experimental Rheumatology, 5(Sup 93), S115-S118. (PMID:26471946)

Full text not currently available from Enlighten.

Publisher's URL:


The cytokines interleukin (IL)-12 and interleukin (IL)-23 have been implicated variously in the pathogenesis of psoriasis and psoriatic arthritis (PsA). By corollary, the IL-12/23 inhibitor, Ustekinumab has been developed as an approved therapeutic for the skin and musculoskeletal syndrome of psoriasis / PsA. This review describes briefly the role of IL-12 and IL-23 in the pathophysiology of psoriatic arthritis and evaluates trial data that support its clinical use in psoriasis and different manifestations of psoriatic arthritis. The next steps towards targeting this pathway also are discussed.

Item Type:Articles
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain and Johnsson, Dr Hanna
Authors: Johnsson, H.J., and McInnes, I.B.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Clinical and Experimental Rheumatology
Publisher:Pacini Editore SpA
ISSN (Online):1593-098X

University Staff: Request a correction | Enlighten Editors: Update this record